RESUMO
t=2.331,P=0.022) T cell levels and CD4+/CD8+ ratio (1.1 ± 0.2vs. 0.9 ± 0.2;t=4.488,P<0.001) showed significant difference between post-treatment and pretreatment. CD3+, CD4+, CD8+ T cell levels and CD4+/CD8+ ratio after treatment showed significant different between the two groups (t values were 3.920, 11.966, 5.573, 10.700,P<0.01). After the treatment, the cure rate in treatment group was significantly higher than that in the control group (80%vs. 56%;χ2=5.561,P=0.018). The rates of sputum conversion from positive to negative (72.0%vs. 50.0%;χ2=5.086,P=0.024)and cavity closure (36.0%vs. 16.0%;χ2=5.198,P=0.023) 6 months after treatment in the treatment group were higher than those in the control group.ConclusionFeitai capsule combined with mycobacterium vaccae can significantly improve the immune function in elderly patients with pulmonary tuberculosis.
RESUMO
Objective Feitai Capsule,a compound of traditional Chinese herbal medicine,has been screened and refined repeatedly for many years and shown to have a good anti-tumor effect.Strict quality control and further screening of the efficacious components of the compound are of great clinical significance.The purpose of this study was to establish the methods for determining the isofraxidin content in Feitai Capsule.Methods We determined the content of isofraxidin in Feitai Capsule by high performance liquid chromatography (HPLC),using the chromatographic column Hypersil ODS-C18 (4.6 mm?150 mm,5 ?m),with the mobile phase as acetonitrile 0.2% phosphoric acid solution (21∶79),the flow rate of 1.0 ml/min,the detective wavelength of 344 nm and the column temperature at 30℃.Results Isofraxidin showed a good linearity,within the range of 2.00-10.80 ?g/ml (y=69 427x+15961,r = 0.999 9),with the average recovery of 97.89% and RSD of 1.64% (n = 6).Conclusion HPLC,accurate and reproducible,is suitable for the determination of the isofraxidin content in Feitai Capsule.
RESUMO
Objective To evaluate the clinical efficacy and safety of Feitai capsule and antituberculosis agents in initially treatment of pulmonary tuberculosis patients. Methods:38 patients were administrated with Feitai capsule and antituberculosis agents for6 months. 15 patients were treated with placebo and anti-tuberculosis angents for 6 months. The changes were observed at 2 and 6 months after treatment, which were changes of sputum smear from positive to negative, lesions and cavities on radiography. Adverse drug reactions were observed during the whole treatment course. Results:The duration of change in sputum tuberculosis smear from positive to negative was short and the absorption rates of lesions and cavities on radiography were greater in the group of Feitai capsule than those of the control group. No evident adverse drug reaction was found. Conclusion: Feitai capsule is a kind of traditional Chinese medicine that accelerates the improvement of pulmonary tuberculosis patients at initial treatment stage as antituberculosis agent. It is effective and safe.